The TRPV4 antagonist GSK2193874 or EA‐mediated TRPV4 suppression reduces cerebral infarction and neurological dysfunction in the MCAO/R model by suppressing the activation and proinflammatory polarization of microglia and the mRNA levels of Tnf‐α, Il‐6, and ccl2 [139]. Here, TNF is linked to cerebral infarction.